Skip to Content

Movantik (naloxegol) Disease Interactions

There are 3 disease interactions with Movantik (naloxegol):

Major

Naloxegol (applies to Movantik) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effect of severe hepatic impairment (Child-Pugh Class C) on the pharmacokinetics of naloxegol has not been evaluated, so the use of this drug should be avoided in patients with this condition. No dose adjustment is required for patients with mild or moderate hepatic impairment.

Major

Peripheral opioid receptor antagonists (applies to Movantik) intestinal obstruction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Diverticulitis, Peptic Ulcer, Inflammatory Bowel Disease

Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.

Moderate

Peripheral opioid receptor antagonists (applies to Movantik) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function. A dose reduction is recommended for these patients. No dosage adjustment is needed in patients with mild renal impairment.

Movantik (naloxegol) drug interactions

There are 169 drug interactions with Movantik (naloxegol)

Movantik (naloxegol) alcohol/food interactions

There is 1 alcohol/food interaction with Movantik (naloxegol)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.